Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab

Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab

We have recently revealed that the new SARS-CoV-2 Omicron sublineages BA.4 and BA.5 exhibit increased resistance to cilgavimab, a therapeutic monoclonal antibody, and the resistance to cilgavimab is attributed to the spike L452R substitution. However, it remains unclear how the spike L452R substitut...

Full description

Bibliographic Details
Main Authors:	Shigeru Fujita, Yusuke Kosugi, Izumi Kimura, Daichi Yamasoba, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Kei Sato
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Viruses
Subjects:	SARS-CoV-2 COVID-19 Omicron BA.4 BA.5 cilgavimab
Online Access:	https://www.mdpi.com/1999-4915/14/12/2677

Similar Items

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
by: Eveline Santos da Silva, et al.
Published: (2023-02-01)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024-12-01)

Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data
by: Yosuke Hirotsu, et al.
Published: (2022-09-01)

Clinical Manifestations of Infections with the Omicron Sub-Lineages BA.1, BA.2, and BA.5: A Retrospective Follow-Up Analysis of Public Health Data from Mecklenburg-Western Pomerania, Germany
by: Katja Verena Goller, et al.
Published: (2024-03-01)

Estimating relative generation times and reproduction numbers of Omicron BA.1 and BA.2 with respect to Delta variant in Denmark
by: Kimihito Ito, et al.
Published: (2022-06-01)

SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals
by: Maarten E. Emmelot, et al.
Published: (2022-12-01)

Differences in Clinical Presentations of Omicron Infections with the Lineages BA.2 and BA.5 in Mecklenburg-Western Pomerania, Germany, between April and July 2022
by: Katja Verena Goller, et al.
Published: (2022-09-01)

SARS‐CoV‐2 Omicron (BA.4, BA.5) variant: Lessons learned from a new variant during the COVID‐19 pandemic
by: Gisou Erabi, et al.
Published: (2024-02-01)

Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection
by: Maja Sočan, et al.
Published: (2024-02-01)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
by: Alexander Wilhelm, et al.
Published: (2022-08-01)

Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa
by: Mary-Ann Davies, et al.
Published: (2023-02-01)

The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID‐19 preventive measures: A threat to global public health
by: Md. Rabiul Islam, et al.
Published: (2022-11-01)

First sequenced cases of Omicron BA.2 sublineage in Ecuador
by: D.A. Andrade-Molina, et al.
Published: (2023-09-01)

Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters
by: Sreelekshmy Mohandas, et al.
Published: (2023-06-01)

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees
by: Francesca Dapporto, et al.
Published: (2022-11-01)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
by: Bingjie Hu, et al.
Published: (2022-12-01)

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
by: Anupriya Aggarwal, et al.
Published: (2022-10-01)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
by: Daria S. Fomina, et al.
Published: (2023-10-01)

Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions
by: Saathvik R. Kannan, et al.
Published: (2022-05-01)

Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater
by: Alexander Wilhelm, et al.
Published: (2022-08-01)

Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe
by: Evangelia Georgia Kostaki, et al.
Published: (2022-12-01)

Virological Characteristics of Five SARS-CoV-2 Variants, Including Beta, Delta and Omicron BA.1, BA.2, BA.5
by: Yan Zeng, et al.
Published: (2023-12-01)

Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients
by: Cesare Ernesto Maria Gruber, et al.
Published: (2023-10-01)

Hot Climate and Humidity Do Not Interfere with BA.5 Omicron Spreading
by: Maria Grazia Cusi, et al.
Published: (2023-02-01)

Discrimination of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 Using a High-Resolution Melting-Based Assay: a Pilot Study
by: Akira Aoki, et al.
Published: (2022-08-01)

Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
by: Haruka Maeda, et al.
Published: (2023-12-01)

Research of Epidemiologic Feature and Control of SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
by: Yu WU, Jue LIU, Min LIU, Wannian LIANG
Published: (2022-10-01)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
by: Jinyoung Yang, et al.
Published: (2023-03-01)

Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review
by: Giorgio Tiecco, et al.
Published: (2022-06-01)

Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127
by: Chengzhuo Tong, et al.
Published: (2022-09-01)

Viral load of SARS‐CoV‐2 Omicron BA.5 is lower than that of BA.2 despite the higher infectivity of BA.5
by: Yuna Takatsuki, et al.
Published: (2023-02-01)

The derived neutrophil to lymphocyte ratio can be the predictor of prognosis for COVID-19 Omicron BA.2 infected patients
by: Weiji Qiu, et al.
Published: (2022-11-01)

Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants
by: Sivaprakasam T. Selvavinayagam, et al.
Published: (2022-09-01)

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5Research in context
by: Huiping Shuai, et al.
Published: (2023-09-01)

Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study
by: Mohammadreza Salehi, et al.
Published: (2023-04-01)

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis
by: Luke B. Elias, et al.
Published: (2023-12-01)

Estimating the incubation period of SARS-CoV-2 Omicron BA.1 variant in comparison with that during the Delta variant dominance in South Korea
by: Yanwen Liu, et al.
Published: (2022-12-01)

The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage
by: Ronghui Liang, et al.
Published: (2022-12-01)

Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021
by: Hanna Vauhkonen, et al.
Published: (2022-06-01)

Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2
by: Alwaleed Behzad, et al.
Published: (2024-02-01)